Innovent Biologics collaborates with Shenzhen Chipscreen Biosciences
20 February 2019 -

Innovent Biologics, a China-based pharmaceutical company, has collaborated with Shenzhen Chipscreen Biosciences, to assess a combination therapy made up of their respective drugs in colorectal cancer patients, it was reported yesterday.

According to the collaboration, both parties will assess the safety and tolerability of the combination therapy of Innovent's Tyvyt (generic name: sintilimab injection), a fully human anti-programmed cell death protein one (anti-PD-1) monoclonal antibody and IBI305, a biosimilar product candidate of bevacizumab and a recombinant humanised anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody, with Chipscreen Biosciences' Chidamide, a benzamide-based selective inhibitor of class I (subtypes 1, 2, 3) and IIb (subtype 10) histone deacetylases (HDACs), in patients with advanced colorectal cancer.

According to the terms of the contract, both firms will work jointly in China to explore potential applications of this combination on colorectal cancer and to assess its safety and tolerability.